ArticleBMC bioinformatics2019
RF_Purify: a novel tool for comprehensive analysis of tumor-purity in methylation array data based on random forest regression.
Article in BMC bioinformatics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- Complementary use of the DNA methylation-based tumor classification by the Bethesda v3 classifier in routine diagnostics: evaluation in a series of 516 cases.Acta neuropathologica · 2026Article
- Distinct molecular subgroups in pediatric and young-onset meningiomas require age-adapted risk stratification.Nature communications · 2026Article
- DNA methylation-based classification of hematolymphoid neoplasms.Blood advances · 2026Article
- MOSAIC: Methylation-Oriented Site Analysis and Information Classifier for Robust Epigenomic Classification of Acute Leukemia in Clinical Cohorts with Variable Tumor Purity.medRxiv : the preprint server for health sciences · 2026Article
- IFN signaling is associated with radiotherapy response in malignant peripheral nerve sheath tumors.The Journal of clinical investigation · 2026Article
- A microenvironment-determined risk continuum refines subtyping in meningioma and reveals determinants of machine learning-based tumor classification.Nature genetics · 2026Article
- Intratumoral preservation of the stem-like malignant cell proportion in glioblastoma, prognostic impact, and its radiomethylomic signatures.Neuro-oncology · 2025Article
- Subtyping Burkitt Lymphoma by DNA Methylation.Genes, chromosomes & cancer · 2025Article
- DNA Methylation Array Analysis Identifies Biological Subgroups of Cutaneous Melanoma and Reveals Extensive Differences with Benign Melanocytic Nevi.Diagnostics (Basel, Switzerland) · 2025Article
- Accurate identification of primary site in tumors of unknown origin (TUO) using DNA methylation.NPJ precision oncology · 2025Article
- Papillary tumor of the pineal region: analysis of DNA methylation profiles and clinical outcomes in 76 cases.Acta neuropathologica communications · 2024Article
- A prognostic neural epigenetic signature in high-grade glioma.Nature medicine · 2024Article
- Molecular and clinicopathologic characteristics of CNS embryonal tumors with BRD4::LEUTX fusion.Acta neuropathologica communications · 2024Article
- Temporal change of DNA methylation subclasses between matched newly diagnosed and recurrent glioblastoma.Acta neuropathologica · 2024Article
- Unclassifiable CNS tumors in DNA methylation-based classification: clinical challenges and prognostic impact.Acta neuropathologica communications · 2024Article
- Epigenetic reprogramming shapes the cellular landscape of schwannoma.Nature communications · 2024Article
- Epigenetic profiling reveals a strong association between lack of 5-ALA fluorescence andNeuro-oncology practice · 2023Article
- Epigenetic neural glioblastoma enhances synaptic integration and predicts therapeutic vulnerability.bioRxiv : the preprint server for biology · 2023Article
- ExosomePurity: tumour purity deconvolution in serum exosomes based on miRNA signatures.Briefings in bioinformatics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundWith the advent of array-based techniques to measure methylation levels in primary tumor samples, systematic investigations of methylomes have widely been performed on a large number of tumor entities. Most of these approaches are not based on measuring individual cell methylation but rather the bulk tumor sample DNA, which contains a mixture of tumor cells, infiltrating immune cells and other stromal components. This raises questions about the purity of a certain tumor sample, given the varying degrees of stromal infiltration in different entities. Previous methods to infer tumor purity require or are based on the use of matching control samples which are rarely available. Here we present a novel, reference free method to quantify tumor purity, based on two Random Forest classifiers, which were trained on ABSOLUTE as well as ESTIMATE purity values from TCGA tumor samples. We subsequently apply this method to a previously published, large dataset of brain tumors, proving that these models perform well in datasets that have not been characterized with respect to tumor purity .
resultsUsing two gold standard methods to infer purity - the ABSOLUTE score based on whole genome sequencing data and the ESTIMATE score based on gene expression data- we have optimized Random Forest classifiers to predict tumor purity in entities that were contained in the TCGA project. We validated these classifiers using an independent test data set and cross-compared it to other methods which have been applied to the TCGA datasets (such as ESTIMATE and LUMP). Using Illumina methylation array data of brain tumor entities (as published in Capper et al. (Nature 555:469-474,2018)) we applied this model to estimate tumor purity and find that subgroups of brain tumors display substantial differences in tumor purity.
conclusionsRandom forest- based tumor purity prediction is a well suited tool to extrapolate gold standard measures of purity to novel methylation array datasets. In contrast to other available methylation based tumor purity estimation methods, our classifiers do not need a priori knowledge about the tumor entity or matching control tissue to predict tumor purity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.